Tracers / [111In]pb12

[111In]pb12

Also written as [In-111]In-pb12

Radionuclide: In-111 t½ 4031.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 2

Breast cancer Preclinical only, no clinical indication yet

What it is

Compound class: DOTA-conjugated neuropeptide-Y (NPY) analogue peptide
Target / mechanism: Human Y1 receptor (hY1R), a G protein-coupled receptor overexpressed on cancer cells PMID 32124111
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	—	92	DOTA-peptide (pb12)	32124111 2020 EJNMMI Res radiolabeling with 111In, 111InCl3 (Curium Netherlands B.V, ~ 250 MBq) was incubated at room temperature with 50 μg of DOTA-peptide (pb12 or pb13) in 500 μL of 0.1 M acetate buffer (pH 5) for 1.5 h under gentle agitation.
—	—	—	—	—	18B7	17875799 2007 Clin Cancer Res 111In-labeled 18B7 and its F(ab')2 and Fab fragments

Need this precursor?We can point you to suppliers for [111In]pb12, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 32124111. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 32124111: 'DOTA-peptide (pb12 or pb13)'.